|
Phase II Study of Eribulin Mesylate and Trastuzumab for Locally Recurrent or Metastatic HER2-Positive Breast Cancer
Vahdat L et al. Eribulin mesylate + trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer: Results from a Phase 2, multicenter, single-arm study. San Antonio Breast Cancer Symposium 2012;Abstract P5-20-04.
Dr Carey is Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research, Chief of the Division of Hematology and Oncology, Physician-in-Chief at the North Carolina Cancer Hospital and Associate Director for Clinical Research at the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina.
Dr Perez is Deputy Director at Large of the Mayo Clinic Cancer Center, Group Vice Chair of the Alliance of Clinical Trials in Oncology and Serene M and Frances C Durling Professor of Medicine at the Mayo Clinic in Jacksonville, Florida.
|
